NNNN
Anbio BiotechnologyAnbio Biotechnology operates in the In Vitro & In Vivo Diagnostic Substances industry.
The numbers · FY2025, filed
SEC EDGARAll filed figures
Snapshot
SEC EDGAR · FY 2025-12-31Revenue by fiscal year
Operating leverage — margins
Financials, annual · income and cash flowSEC EDGAR · open ▸
Financials — annual
SEC EDGAR · last 4 FY · tap a row to explain it| USD | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $23.5M | $6.7M | $8.2M | $8.6M |
| Gross Profit | $12.6M | $3.4M | $5.9M | $7.5M |
| Operating Income | $10.2M | $2.0M | $2.0M | $5.8M |
| Net Income | $10.0M | $2.3M | $2.4M | $6.4M |
| Diluted EPS | $100112.00 | $0.10 | $0.06 | $0.15 |
| Operating Cash Flow | $4.4M | $898,367 | $2.1M | $-6.7M |
| Free Cash Flow | — | — | — | — |
Same industry
In the screener →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.